Fact-check: Yale Medicine on medical therapies for weight management

What the video covers

Several Yale clinicians speak in turn: the defended fat-mass set point again; incretin hormones as fullness signals and the new drugs as imitations of them; that the clinical trials always combined the drug with a calorie deficit and moderate exercise, so medication is one step in a comprehensive program; that response varies from very large losses to none; and that medication can be combined with endoscopic options such as intragastric balloons or endoscopic sleeve gastroplasty, which restrict intake without removing any stomach.

What it gets right

Each point is correct. The label indication for Wegovy and Zepbound is as an adjunct to a reduced-calorie diet and increased physical activity, which is the trial design the video describes. The variability claim is borne out by the responder analyses. In STEP 1, 86 percent of the semaglutide group lost at least 5 percent, 69 percent at least 10 percent, 51 percent at least 15 percent and 32 percent at least 20 percent, which means about one in seven lost less than 5 percent and about one in three lost 20 percent or more (PubMed 33567185). In SURMOUNT-1 at 15 mg, 91 percent lost at least 5 percent and 57 percent lost at least 20 percent (PubMed 35658024). "Your obesity may be different from somebody else's" is a fair reading of that spread.

The description of endoscopic sleeve gastroplasty as suturing the stomach smaller without removal is accurate, and the "multimodal therapy" framing is how most academic weight-management programs work.

What it leaves out or overstates

The illustrative figures ("50, 60, 80 pounds" for strong responders, "10 or 15 pounds" for weak ones) are examples, not data. The published distributions above are what to quote. The video also does not say that a prescriber cannot currently predict who will respond, which UCSF's grand rounds later in this playlist covers, nor that the labels' responder logic (for older agents, stop if less than 5 percent lost by a set week) does not appear in the semaglutide and tirzepatide labels.

Nothing on side effects, cost, or the requirement to continue the drug, and nothing on the evidence for combining a GLP-1 with an endoscopic procedure, which is thinner than the evidence for either alone.

Where to go next

The UCSF grand rounds later in this playlist gives one-year and two-year figures for every approved agent. For the responder distributions applied to your weight, with the caveat that averages are not individuals, use the projection tool on FormBlends Calculators. Choosing a GLP-1 Clinic explains what a comprehensive program should include. FormBlends' compounded products, described at formblends.com, are not FDA approved and were not the products in these trials.